Screening for content—the evolution of high throughput (original) (raw)

Nature Biotechnology volume 21, pages 859–864 (2003)Cite this article

Despite a poor return on investment thus far, innovations in high-throughput screening are still very much in demand.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Figure 1: Waning drug approvals.

Figure 2: High throughput screening alliances.

Source: Recombinant Capital

Figure 3: A 900-data point profile with Akceli cell microarrays.

Image courtesy of Akceli.

Figure 4: Avidin-rhodamine staining of liver of an intact zebrafish embryo.

Image courtesy Phylonix.

References

Author information

Authors and Affiliations

  1. Contributing Writer at Nature Biotechnology,
    Alan Dove

Authors

  1. Alan Dove
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Dove, A. Screening for content—the evolution of high throughput.Nat Biotechnol 21, 859–864 (2003). https://doi.org/10.1038/nbt0803-859

Download citation

This article is cited by